Navigation Links
Estrogen-dependent switch tempers killing activity of immune cells
Date:8/10/2009

The sex hormone estrogen tempers the killing activity of a specific group of immune cells, the cytotoxic T cells (CTLs), which are known to attack tumor cells and cells infected by viruses. The key player in this process is a cytotoxic T cell molecule which has been known for a long time and which scientists have named EBAG9. Cancer researchers Dr. Constantin Rder and Dr. Armin Rehm together with immunologist Dr. Uta Hpken of the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch and Charit University Medicine Berlin, Germany, have now unraveled the function of EBAG9. Modulated by estrogen, EBAG9 tempers the activity of CTLs. In the absence of EBAG9, the activity of CTLs is enhanced (Journal of Clinical Investigation, Vol. 119, No. 8, pp 2184-2203, August 3, 2009)*.

The sex hormone estrogen plays a critical role in the regulation of growth and the development of cells. It is also crucial for cell-type-specific gene expression in various tissues. Deregulation of this system results in breast and ovarian cancer.

Those tumors are successfully treated with drugs such as tamoxifen. Researchers suggest that this drug inhibits tumor growth by blocking the estrogen receptors of the tumor cells. However, up to now it has been unclear what effect this inhibition has on the immune system.

In a previous study, Japanese researchers detected large amounts of EBAG9 in estrogen-dependent tumors. Dr. Rehm and his colleagues wondered what effect elevated levels of estrogen would have on cytotoxic T cells that attack tumors. They assumed that EBAG9 could transmit this effect of estrogen and therefore wanted to know what would happen if they knocked out the gene for EBAG9 in mice.

After knocking out the gene for EBAG9, they found that in the absence of EBAG9 the "brake" of the immune cells is loosened. The immune cells can release much more of the tumor-killing enzymes than in the presence of EBAG9. The deathly harbingers are stored in granules (secretory lysosomes) in the cytotoxic T cells. They have greater quantities of these granules at their disposal once the blockage of the immune cells through EBAG9 is lifted.

These findings of the researchers in Berlin may also explain why drugs like tamoxifen act on tumor cell growth. One argument is that once the estrogen receptors of the tumor cells are inhibited by the drug, the sex hormone can no longer promote tumor growth. At the same time EBAG9 can no longer inhibit the cytotoxic T cells. The immune cells are ready to attack and destroy the tumor cells.

"In this way, tamoxifen not only inhibits tumor growth but may also be able to enhance the effect of the immune system," Dr. Rehm said. His working hypothesis is that EBAG9 acts as a molecular switch which regulates the immune cells.

As a next step, he and his colleagues plan to study cytotoxic T cells from patients with estrogen-dependent tumors to see if EBAG9 levels are increased.


'/>"/>

Contact: Barbara Bachtler
bachtler@mdc-berlin.de
49-309-406-3896
Helmholtz Association of German Research Centres
Source:Eurekalert

Related biology news :

1. Switching goals
2. Researchers find signal that switches on eye development -- could lead to eye in a dish
3. Researchers identify how to switch off cancer cell genes
4. Leading cause of death in preemies might be controlled by resetting a molecular switch
5. Why the switch stays on
6. Electronic switch opens doors in rheumatoid joints
7. Search for the on switches may reveal genetic role in development and disease
8. A switch that controls whether cells pass point of no return
9. Nanodrop test tubes created with a flip of a switch
10. Berkeley researchers identify photosynthetic dimmer switch
11. A molecular switch turns on the flame in natures blowtorch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
Breaking Biology Technology: